Maleate salts of a quinazoline derivative useful as an antiangiogenic agent
AssigneeAstraZeneca AB
InventorJames MCCABE
Life of this patent
Estimating the term…
Abstract
The present invention relates to AZD2171 maleate salt, to particular crystalline forms of AZD2171 maleate salt, to processes for their preparation, to pharmaceutical compositions containing them as active ingredient, to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to their use in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability.
Claims6
1-20. (canceled)
A method for inhibiting VEGF receptor tyrosine kinase in a warm-blooded animal in need of such treatment which comprises
- orally administering to said animal an effective amount of a pharmaceutical composition comprising crystalline Form A of 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline maleate, wherein said warm-blooded animal in need of such treatment has a solid tumor cancer that is recurrent, and
- optionally administering at least one additional treatment chosen from surgery, radiotherapy, and chemotherapy.
Dependencies are inferred from the claim text.